These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21939627)

  • 1. The role of gap junctions in the arrhythmias of ischemia and infarction.
    Wit AL; Peters NS
    Heart Rhythm; 2012 Feb; 9(2):308-11. PubMed ID: 21939627
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug development for treatment of cardiac arrhythmias: targeting the gap junctions.
    Wit AL; Duffy HS
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H16-8. PubMed ID: 17890421
    [No Abstract]   [Full Text] [Related]  

  • 3. Increasing gap junctional coupling: a tool for dissecting the role of gap junctions.
    Axelsen LN; Haugan K; Stahlhut M; Kjølbye AL; Hennan JK; Holstein-Rathlou NH; Petersen JS; Nielsen MS
    J Membr Biol; 2007 Mar; 216(1):23-35. PubMed ID: 17568971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological modulation of connexin-formed channels in cardiac pathophysiology.
    De Vuyst E; Boengler K; Antoons G; Sipido KR; Schulz R; Leybaert L
    Br J Pharmacol; 2011 Jun; 163(3):469-83. PubMed ID: 21265827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rationale of magnesium supplementation in acute myocardial infarction. A review of the literature.
    Shechter M; Kaplinsky E; Rabinowitz B
    Arch Intern Med; 1992 Nov; 152(11):2189-96. PubMed ID: 1444677
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and experimental study of antiarrhythmic and antianginal effects of quaternidine.
    Kostin YV; Sernov LN; Moiseeva IY; Kulikova NN; Shmyreva MV; Klimovich YG
    Bull Exp Biol Med; 2000 Nov; 130(11):1113-5. PubMed ID: 11182831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New insights into the pharmacology of sodium channel blockers.
    Tamargo J; Valenzuela C; Delpón E
    Eur Heart J; 1992 Nov; 13 Suppl F():2-13. PubMed ID: 1335869
    [No Abstract]   [Full Text] [Related]  

  • 8. Computational model of erratic arrhythmias in a cardiac cell network: the role of gap junctions.
    Casaleggio A; Hines ML; Migliore M
    PLoS One; 2014; 9(6):e100288. PubMed ID: 24941068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Importance and risks of drugs in the treatment of arrhythmias due to infarction].
    Fourrié JL; Libersa CC
    Soins Cardiol; 1984 Feb; (12):26-33. PubMed ID: 6562734
    [No Abstract]   [Full Text] [Related]  

  • 10. Gap junctions enhancer combined with Vaughan Williams class III antiarrhythmic drugs, a promising antiarrhythmic method?
    Li LD; Zhang CT; Ruan L; Ni MK; Quan XQ
    Med Hypotheses; 2011 Jan; 76(1):119-21. PubMed ID: 20889260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myocardial architecture and ventricular arrhythmogenesis.
    Peters NS; Wit AL
    Circulation; 1998 May; 97(17):1746-54. PubMed ID: 9591770
    [No Abstract]   [Full Text] [Related]  

  • 12. The monophasic action potential technique and its application in cardiac electropharmacology.
    Xie JT; January CT
    Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):557-67. PubMed ID: 8309319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cardiac arrhythmias (III). The classification of anti-arrhythmia drugs in the 90s: a focus for the cardiologist].
    Tamargo J; Valenzuela C; Delpón E
    Rev Esp Cardiol; 1993 Mar; 46(3):183-94. PubMed ID: 8387683
    [No Abstract]   [Full Text] [Related]  

  • 14. Pharmacological modulation of gap junction function with the novel compound rotigaptide: a promising new principle for prevention of arrhythmias.
    Kjølbye AL; Haugan K; Hennan JK; Petersen JS
    Basic Clin Pharmacol Toxicol; 2007 Oct; 101(4):215-30. PubMed ID: 17845503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gap junction channel in the development of beat-to-beat action potential repolarization variability and arrhythmias.
    Magyar J; Banyasz T; Szentandrassy N; Kistamas K; Nanasi PP; Satin J
    Curr Pharm Des; 2015; 21(8):1042-52. PubMed ID: 25354184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac arrhythmogenesis and the gap junction.
    Peters NS; Green CR; Poole-Wilson PA; Severs NJ
    J Mol Cell Cardiol; 1995 Jan; 27(1):37-44. PubMed ID: 7760358
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacological modulation of cardiac gap junctions to enhance cardiac conduction: evidence supporting a novel target for antiarrhythmic therapy.
    Eloff BC; Gilat E; Wan X; Rosenbaum DS
    Circulation; 2003 Dec; 108(25):3157-63. PubMed ID: 14656916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-arrhythmia and antifibrillatory effect of flecainide in programmed ventricle stimulation and in recent heart infarction].
    Thale J; Gülker H; Bender F; Heuer H
    Med Welt; 1982 Jul; 33(26):965-6. PubMed ID: 7109955
    [No Abstract]   [Full Text] [Related]  

  • 19. What is an antiarrhythmic drug? From clinical trials to fundamental concepts.
    Nattel S; Waters D
    Am J Cardiol; 1990 Jul; 66(1):96-9. PubMed ID: 2360538
    [No Abstract]   [Full Text] [Related]  

  • 20. Functional, structural, and dynamic basis of electrical heterogeneity in healthy and diseased cardiac muscle: implications for arrhythmogenesis and anti-arrhythmic drug therapy.
    Wolk R; Cobbe SM; Hicks MN; Kane KA
    Pharmacol Ther; 1999 Nov; 84(2):207-31. PubMed ID: 10596907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.